Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Corrigan

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Clinical Pharmacology|July 2, 2016
Utility of Model-Based Approaches for Informing Dosing Recommendations in Specific Populations: Report From the Public AAPS WorkshopIslam R Younis, J Robert Powell, Amin Rostami-Hodjegan, et al.
Clinical Pharmacology and Therapeutics|August 19, 2023
Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and ImplementationKatty Wan, Olga Kavetska, Bharat Damle, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trialsSteven X Xu, Mahesh N Samtani, Alberto Russu, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumabMahesh N Samtani, Steven X Xu, Alberto Russu, et al.
Journal of Alzheimer'S Disease : JAD|May 11, 2016
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of BapineuzumabAlberto Russu, Mahesh N Samtani, Steven Xu, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Accelerating drug development for Alzheimer's disease through the use of data standardsJon Neville, Steve Kopko, Klaus Romero, et al.
Clinical Pharmacology and Therapeutics|June 17, 2022
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal ImpairmentSima S Toussi, Joel Michael Neutel, Jesus Navarro, et al.
Clinical Pharmacology and Therapeutics|January 20, 2020
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open DataDaniela J Conrado, Sridhar Duvvuri, Hugo Geerts, et al.
Clinical and Translational Science|July 28, 2017
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling AnalysisDaniela J Conrado, Timothy Nicholas, Kuenhi Tsai, et al.
Contemporary Clinical Trials|May 3, 2021
Demographic diversity of participants in Pfizer sponsored clinical trials in the United StatesMelinda Rottas, Peter Thadeio, Rachel Simons, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pharmacology|July 2, 2016
Utility of Model-Based Approaches for Informing Dosing Recommendations in Specific Populations: Report From the Public AAPS WorkshopIslam R Younis, J Robert Powell, Amin Rostami-Hodjegan, et al.
Clinical Pharmacology and Therapeutics|August 19, 2023
Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and ImplementationKatty Wan, Olga Kavetska, Bharat Damle, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trialsSteven X Xu, Mahesh N Samtani, Alberto Russu, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumabMahesh N Samtani, Steven X Xu, Alberto Russu, et al.
Journal of Alzheimer'S Disease : JAD|May 11, 2016
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of BapineuzumabAlberto Russu, Mahesh N Samtani, Steven Xu, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Accelerating drug development for Alzheimer's disease through the use of data standardsJon Neville, Steve Kopko, Klaus Romero, et al.
Clinical Pharmacology and Therapeutics|June 17, 2022
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal ImpairmentSima S Toussi, Joel Michael Neutel, Jesus Navarro, et al.
Clinical Pharmacology and Therapeutics|January 20, 2020
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open DataDaniela J Conrado, Sridhar Duvvuri, Hugo Geerts, et al.
Clinical and Translational Science|July 28, 2017
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling AnalysisDaniela J Conrado, Timothy Nicholas, Kuenhi Tsai, et al.
Contemporary Clinical Trials|May 3, 2021
Demographic diversity of participants in Pfizer sponsored clinical trials in the United StatesMelinda Rottas, Peter Thadeio, Rachel Simons, et al.
Pageof 4